Skip to main content

Oregon State Flag An official website of the State of Oregon »

Prescription drug data

Each calendar year, the board shall identify nine drugs and at least one insulin product under ORS 646A.694 that the board determines may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state. The Oregon Prescription Drug Price Transparency program provides the board with the list of prescription drugs for review submitted under ORS 646A.689 (2) and (6), and ORS 743.025. This page contains aggregated data files for the board's affordability review as outlined in OAR 925.200.0010 and OAR 925.200.0020. The board strictly maintains the confidentiality of any information collected, used or relied upon for the review that is protected trade secret, confidential, or proprietary information, as defined in ORS 192.345.

Jan. 26, 2024 affordability review reports

Jan. 10, 2024 affordability review reports

Prescription drug and insulin list for affordability review (approved by the board on Dec. 13, 2023)

Dec. 13, 2023 board revised subset lists

On November 15, 2023 the board selected subsets for prescription drugs and insulin pursuant to OAR-925-200-0010

  • Oregon PDAB drug and insulin subset lists (PDF)
Data for board review on November 15, 2023

On October 18, 2023, the board selected a subset list of prescription drugs pursuant to OAR 925-200-0010

Data for board review on October 18, 2023

Data for board review on September 20, 2023